Germany’s smaller stock market segments contain a number of pearls that many investors may not yet have noticed. One of the strongest stocks for years has been the provider of isotope technology for medical, scientific and industrial use – Eckert & Ziegler. The company is now listed on the German SDAX index and has a market capitalization of USD 2.62 billion.
As a supplier of radioactive components to pharmaceutical companies, the Group has positioned itself strongly and benefits from extremely high barriers to market entry in the segments Medical and Isotope Products.
In the first half of 2021, Eckert & Ziegler reported a new record result with a net profit of €22.3 million or €1.08 per share. Compared to the same period of the previous year, groups earnings increased significantly by €9.4 million or 73%.
As part of a duopoly, the company can benefit from advantages in pricing and the growing demand for cancer therapies. In July, the company acquired Ambientis Radioprotecao, based in Sao Paulo, Brazil. The synergies created by the acquisiton will increase market opportunities for both the industrial segment and the radiopharma and nuclear medicine segments in the region.
Eckert & Ziegler is focusing on organic growth as well as strategic acquisitions in the expansion of its business. This acquisition is a further step in our growth strategy in South America, one of the world’s most dynamic healthcare markets.
The share price increased by 1.900% in the last 5 years and sits just 29% away from its record.